402 related articles for article (PubMed ID: 15849513)
1. Neuroendocrine hepatic metastases: does aggressive management improve survival?
Touzios JG; Kiely JM; Pitt SC; Rilling WS; Quebbeman EJ; Wilson SD; Pitt HA
Ann Surg; 2005 May; 241(5):776-83; discussion 783-5. PubMed ID: 15849513
[TBL] [Abstract][Full Text] [Related]
2. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.
Gupta S; Yao JC; Ahrar K; Wallace MJ; Morello FA; Madoff DC; Murthy R; Hicks ME; Ajani JA
Cancer J; 2003; 9(4):261-7. PubMed ID: 12967136
[TBL] [Abstract][Full Text] [Related]
3. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
[TBL] [Abstract][Full Text] [Related]
4. Metastatic neuroendocrine hepatic tumors: resection improves survival.
Musunuru S; Chen H; Rajpal S; Stephani N; McDermott JC; Holen K; Rikkers LF; Weber SM
Arch Surg; 2006 Oct; 141(10):1000-4; discussion 1005. PubMed ID: 17043278
[TBL] [Abstract][Full Text] [Related]
5. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
[TBL] [Abstract][Full Text] [Related]
6. Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma.
Arrese D; McNally ME; Chokshi R; Feria-Arias E; Schmidt C; Klemanski D; Gregory G; Khabiri H; Shah M; Bloomston M
Ann Surg Oncol; 2013 Apr; 20(4):1114-20. PubMed ID: 23456380
[TBL] [Abstract][Full Text] [Related]
7. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors.
Diamandidou E; Ajani JA; Yang DJ; Chuang VP; Brown CA; Carrasco HC; Lawrence DD; Wallace S
AJR Am J Roentgenol; 1998 Feb; 170(2):339-44. PubMed ID: 9456942
[TBL] [Abstract][Full Text] [Related]
8. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors.
Clouse ME; Perry L; Stuart K; Stokes KR
Digestion; 1994; 55 Suppl 3():92-7. PubMed ID: 7698544
[TBL] [Abstract][Full Text] [Related]
9. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors.
Yao KA; Talamonti MS; Nemcek A; Angelos P; Chrisman H; Skarda J; Benson AB; Rao S; Joehl RJ
Surgery; 2001 Oct; 130(4):677-82; discussion 682-5. PubMed ID: 11602899
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic neuroendocrine tumors: presentation, management, and outcomes.
Nissen NN; Kim AS; Yu R; Wolin EM; Friedman ML; Lo SK; Wachsman AM; Colquhoun SD
Am Surg; 2009 Oct; 75(10):1025-9. PubMed ID: 19886158
[TBL] [Abstract][Full Text] [Related]
11. Hepatic surgery for metastases from neuroendocrine tumors.
Sarmiento JM; Que FG
Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141
[TBL] [Abstract][Full Text] [Related]
12. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization.
Liapi E; Geschwind JF; Vossen JA; Buijs M; Georgiades CS; Bluemke DA; Kamel IR
AJR Am J Roentgenol; 2008 Jan; 190(1):67-73. PubMed ID: 18094295
[TBL] [Abstract][Full Text] [Related]
13. Hepatic resection for metastatic neuroendocrine carcinomas.
Que FG; Nagorney DM; Batts KP; Linz LJ; Kvols LK
Am J Surg; 1995 Jan; 169(1):36-42; discussion 42-3. PubMed ID: 7817996
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors.
Ho AS; Picus J; Darcy MD; Tan B; Gould JE; Pilgram TK; Brown DB
AJR Am J Roentgenol; 2007 May; 188(5):1201-7. PubMed ID: 17449759
[TBL] [Abstract][Full Text] [Related]
15. Management of hepatic metastasis of gastrointestinal carcinoid tumors.
Landry CS; Scoggins CR; McMasters KM; Martin RC
J Surg Oncol; 2008 Mar; 97(3):253-8. PubMed ID: 18264984
[TBL] [Abstract][Full Text] [Related]
16. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.
Strosberg JR; Choi J; Cantor AB; Kvols LK
Cancer Control; 2006 Jan; 13(1):72-8. PubMed ID: 16508629
[TBL] [Abstract][Full Text] [Related]
17. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy.
Bloomston M; Binitie O; Fraiji E; Murr M; Zervos E; Goldin S; Kudryk B; Zwiebel B; Black T; Fargher S; Rosemurgy AS
Am Surg; 2002 Sep; 68(9):827-31. PubMed ID: 12356160
[TBL] [Abstract][Full Text] [Related]
18. Hepatic neuroendocrine metastases: does intervention alter outcomes?
Chamberlain RS; Canes D; Brown KT; Saltz L; Jarnagin W; Fong Y; Blumgart LH
J Am Coll Surg; 2000 Apr; 190(4):432-45. PubMed ID: 10757381
[TBL] [Abstract][Full Text] [Related]
19. Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases.
Makary MS; Kapke J; Yildiz V; Pan X; Dowell JD
J Vasc Interv Radiol; 2016 Sep; 27(9):1298-1304. PubMed ID: 27499157
[TBL] [Abstract][Full Text] [Related]
20. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
